New hope for kids with stubborn hives: dupixent studied

NCT ID NCT05526521

Completed Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the drug dupilumab (Dupixent) in 15 children aged 2 to 12 who have chronic spontaneous urticaria (CSU), also known as long-lasting hives, that didn't get better with antihistamines. The main goals were to check how the drug behaves in the body and to see if it's safe. The children received injections for 24 weeks and were followed for 12 more weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dupilumab (Dupixent)
What this could lead to: If it works, this could offer a new treatment option for children with chronic hives that don't respond to standard antihistamines.
What could go wrong: This is a small, single-arm study with only 15 participants, so results may not apply to all children. It primarily looked at safety and drug levels, not how well it works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic idiopathic urticaria Chronic Urticaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC SPONTANEOUS URTICARIA

Contacts and locations

Locations

Boston Childrens Health Physicians Site Number : 8400017

Hawthorne, New York, 10532, United States
Childrens Hospital Medical Center of Akron- Site Number : 8400020

Akron, Ohio, 44308, United States
Cincinnati Children's Hospital Medical Center - PIN- Site Number : 8400001

Cincinnati, Ohio, 45229-3026, United States
Columbia University Irving Medical Center Site Number : 8400003

New York, New York, 10032, United States
Investigational Site Number : 1240001

Montreal, Quebec, H4A 3J1, Canada
Investigational Site Number : 1240007

Hamilton, Ontario, L8S1G5, Canada
Investigational Site Number : 1240009

Calgary, Alberta, T2W 4X9, Canada
Investigational Site Number : 1240010

Edmonton, Alberta, T5J 3S9, Canada
Investigational Site Number : 3920001

Yokohama, Kanagawa, 232-8555, Japan
Investigational Site Number : 3920002

Tsu, Mie-ken, 514-0125, Japan
Monroe Carell Jr. Childrens Hospital at Vanderbilt- Site Number : 8400005

Nashville, Tennessee, 37232, United States
Pediatric Dermatology of Miami Site Number : 8400015

Coral Gables, Florida, 33146, United States
Treasure Valley Medical Research Site Number : 8400019

Boise, Idaho, 83706, United States
Vital Prospects Clinical Research Institute, P.C.- Site Number : 8400002

Tulsa, Oklahoma, 74136, United States
Washington University School of Medicine- Site Number : 8400004

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.